Skip to main content
ArticleOPEN ACCESS

BCL-2 inhibition and AML: can we best Darwin?

Blood
DOI: 10.1182/BLOOD.2019004757
2Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, DiNardo and colleagues1 provide fascinating details on the behavior of leukemic clones in less-fit patients treated for acute myeloid leukemia (AML) with the combination of venetoclax and either a hypomethylating agent or a low-dose cytarabine.

Cite

CITATION STYLE

APA

Michaelis, L. C. (2020, March 12). BCL-2 inhibition and AML: can we best Darwin? Blood. American Society of Hematology. https://doi.org/10.1182/BLOOD.2019004757

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free